Invention Grant
- Patent Title: NMDA receptor modulators and uses thereof
-
Application No.: US16471880Application Date: 2017-12-22
-
Publication No.: US11274107B2Publication Date: 2022-03-15
- Inventor: David R. Anderson , Robert A. Volkmann , Frank Menniti , Christopher Fanger , Yuelian Xu
- Applicant: Cadent Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Cadent Therapeutics, Inc.
- Current Assignee: Cadent Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Michael J. DeGrazia
- International Application: PCT/US2017/068135 WO 20171222
- International Announcement: WO2018/119374 WO 20180628
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07D471/04 ; C07D487/04 ; C07D495/04 ; C07D498/04 ; C07D513/20
Abstract:
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
Public/Granted literature
- US20200087323A1 NMDA RECEPTOR MODULATORS AND USES THEREOF Public/Granted day:2020-03-19
Information query
